Trial Information
Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand
Inclusion Criteria:
- Diagnosed as having lung cancer based on histological/cytological findings
- Admitted to the hospital between January 2004 and December 2008
- Treated with gefitinib for at least 3 months
Exclusion Criteria:
- Involvement in the planning and/or conduct of the study
- Participation in another clinical study during the last 3 months
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Progression-free survival
Outcome Time Frame:
median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx.
Safety Issue:
No
Principal Investigator
Virote Sriuranpong, MD., PhD.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Chulalongkorn Hospital, Bangkok, Thailand
Authority:
Thailand: Ethical Committee
Study ID:
NIS-OTH-IRE-2009/1
NCT ID:
NCT01130961
Start Date:
October 2009
Completion Date:
August 2010
Related Keywords:
- Lung Cancer
- Advanced NSCLC
- Gefitinib
- Thai patient
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms